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OBJECTIVE—This retrospective study examined the association between ICD-9-CM–coded
outpatient hypoglycemic events(HEs)and acute cardiovascularevents(ACVEs), i.e., acutemyo-
cardial infarction, coronary artery bypass grafting, revascularization, percutaneous coronary in-
tervention, and incident unstable angina, in patients with type 2 diabetes.
RESEARCH DESIGN AND METHODS—Data were derived from healthcare claims for
individuals with employer-sponsored primary or Medicare supplemental insurance. A baseline
period (30 September 2006 to 30 September 2007) was used to identify eligible patients
and collect information on their clinical and demographic characteristics. An evaluation
period (1 October 2007 to 30 September 2008) was used to identify HEs and ACVEs. Patients
aged $18 years with type 2 diabetes were selected for analysis by a modiﬁed Healthcare
Effectiveness Data and Information Set algorithm. Data were analyzed with multiple logistic
regression and backward stepwise selection (maximum P = 0.01) with adjustment for impor-
tantconfoundingvariables,includingage,sex,geography,insurancetype,comorbidityscores,
cardiovascular risk factors, diabetes complications, total baseline medical expenditures, and
prior ACVEs.
RESULTS—Of the 860,845 patients in the analysis set, 27,065 (3.1%) had ICD-9-CM–coded
HEsduringtheevaluationperiod.Themainmodelretained17signiﬁcantindependentvariables.
Patients with HEs had 79% higher regression-adjusted odds (HE odds ratio [OR] 1.79; 95%
CI 1.69–1.89) of ACVEs than patients without HEs; results in patients aged $65 years were
similar to those for the entire population (HE OR 1.78, 95% CI 1.65–1.92).
CONCLUSIONS—ICD-9-CM–coded HEs were independently associated with an increased
risk of ACVEs. Further studies of the relationship between hypoglycemia and the risk of ACVEs
are warranted.
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T
he long-term complications that re-
sult from poor glycemic control
contribute substantially to the mor-
bidity,mortality,andeconomicburdenof
diabetes. Over time, the hyperglycemia
seeninpatientswithdiabetescanincrease
the risk of both microvascular complica-
tions and result in a two- to fourfold in-
crease in the risk of macrovascular
complications(1–3).Therelationship be-
tween macrovascular complications and
glycated hemoglobin is not understood
precisely; however, atherosclerosis and
vascular occlusion from hypercoagulabil-
ity and increased adhesion of platelets are
thought to occur through various meta-
bolic mechanisms, placing individuals
with diabetes at an increased risk for car-
diovascular disease (4).
Although near normoglycemic con-
trol has been demonstrated to reduce the
incidence of microvascular complications
such as retinopathy, nephropathy, and
neuropathy, the independent effect of
A1C lowering on the risk of cardio-
vascular events in patients with type 2
diabetes is less clear (5–7). Although ob-
servational studies have described the
naturalistic association between hyper-
glycemia and increased cardiovascular
risk in type 2 diabetes, the results of in-
terventional randomized controlled trials
in establishing the cardiovascular beneﬁt
of pharmacotherapeutic management of
hyperglycemia, including intensive ther-
apy, have been inconsistent. The UK Pro-
spective Diabetes Study of patients with
type 2 diabetes reported a substantial but
statistically nonsigniﬁcant (P = 0.052)
16% reduction in cardiovascular compli-
cations (combined fatal or nonfatal myo-
cardial infarction [MI] and sudden death)
between patientsrandomizedtointensive
management and patients randomized to
conventional management over 10 years.
However,datafromanadditional10-year
follow-up study of this same cohort of
patients did show a quantitatively similar
but statistically signiﬁcant long-term car-
diovascular beneﬁt of intensive control
(sulfonylurea-insulin group: relative risk
reduction for MI 15%, P , 0.01; metfor-
min group: relative risk reduction for MI
33%, P = 0.005), even after an intensive
strategy was abandoned (1,8).
Because the clinical trial evidence re-
garding the macrovascular beneﬁto fA 1 C
lowering to traditional A1C targets had
been inconsistent, the Action to Control
CardiovascularRiskinDiabetes(ACCORD),
Action in Diabetes and Vascular Disease:
Preterax and Diamicron Modiﬁed Release
Controlled Evaluation (ADVANCE), and
Veterans Affairs Diabetes Trial (VADT)
sought to explore whether treatment to
more intensive A1C targets (#6.5 or
,6%) might more consistently establish
the macrovascular beneﬁtt h a th a sb e e n
so elusive in studies evaluating less inten-
sive glycemic targeting (5–7). Unfortu-
nately, these trials did not, in general,
demonstrate the macrovascular beneﬁto f
intensive glycemic control. Furthermore,
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ORIGINAL ARTICLEtheﬁndingofincreasedall-causemortality
in the intensively managed cohort of the
ACCORD trial has caused some to reeval-
uate intensive management entirely in
light of what has been perceived by some
as an unfavorable risk-to-beneﬁt ratio (9).
Since the publication of these studies, the
scientiﬁc community has sought a deeper
understanding of the complex relation-
ships among glycemic control, patient co-
morbidity, and cardiovascular morbidity
and mortality in patients with type 2 di-
abetes.Indoingso,somehavefocusedtheir
attention on the role that severe hypoglyce-
mia may play, although this does not seem
to be the primary culprit in ACCORD in
the intensively treated cohort.
Hypoglycemia can trigger a series of
maladaptive sequelae that can alter a pa-
tient’scardiovascularrisk proﬁleandpos-
sibly contribute to increased mortality.
Research has suggested that hypoglyce-
mia may induce hematologic changes
thatrestrictbloodﬂowtothedistaltissues
and encourage thrombosis, stimulate
stress responses that lead to increases in
the expression of inﬂammatory markers
associated with endothelial damage
and the development of vascular disease,
and promote localized vasoconstriction
through hypoglycemia-induced release
of epinephrine (10). Furthermore, re-
search has suggested that hypoglycemia
may impair the counter-regulatory auto-
nomicresponsetosubsequentepisodesof
hypoglycemia. In addition, autonomic
impairment has been shown to be associ-
ated with an increase in the risk of mor-
tality in patients with diabetes (11–13).
Current understanding of the adverse
impact of hypoglycemia provides the
theoreticframeworkthatformstheunder-
pinning of some of the exploratory post
hoc analyses carried out by the ACCORD
and VADT researchers. For example, a
recently published post hoc analysis of
the ACCORD study found that patients
who experienced severe hypoglycemia,
regardless of study arm, exhibited an in-
creased risk of death (14). In addition, an
exploratory analysis of the VADT trial
data found that severe hypoglycemia
within 90 days was a strong predictor of
cardiovascular mortality (15).
Given the unresolved nature of this
importantsubject,thisretrospectiveobser-
vational study was conducted to examine
the association between hypoglycemic
events (HEs) and acute cardiovascular
events (ACVEs) in a large cohort of U.S.
patients with type 2 diabetes in the non-
interventional setting of routine care.
RESEARCH DESIGN AND
METHODS
Data source and patient selection
Data were derived from inpatient, out-
patient, and outpatient prescription drug
claims and encounter records for approx-
imately 43 million employees and depen-
dentswithemployer-sponsoredprimaryor
Medicare supplemental insurance con-
tained in the 2006 to 2008 Thomson Reu-
ters MarketScan Commercial Claims and
Encounters (Commercial) database and
MedicareSupplementalandCoordination
of Beneﬁts (Medicare) database. The data
contained in the Commercial and Medi-
care databases are fully compliant with
the Health Insurance Portability and Ac-
countability Act Privacy Regulations and
statistically de-identiﬁed, exempting this
study from an institutional review board
approval requirement.
Two consecutive years of data from
30 September 2006 to 30 September
2008 were used for this study, which
represented the latest available data in the
Commercial and Medicare databases at
the time that the study was conducted.
The ﬁrst year (baseline period) was used
to select a prevalence-based sample of
patients with type 2 diabetes and identify
their baseline demographic and clinical
information. The second year (evaluation
period) was used to evaluate the presence
of HEs and ACVEs.
Patients meeting the following inclu-
sion criteria during the baseline period
were selected for study:
1a. Modiﬁed Healthcare Effectiveness Data
and Information Set criteria for type 2
diabetesduringbaselineperiod:Atleast
one claim with a diagnosis code for
type 2 diabetes (ICD-9-CM 250. 3 0
or 250. 3 2) and no claims with a di-
agnosis code for type 1 diabetes (ICD-
9-CM = 250. 3 1 or 250. 3 3); or if
claims for type 1 diabetes, the patient
must also have at least one claim for
type 2 diabetes and at least one claim
for an oral antidiabetic drug or the
p a t i e n tm u s th a v em o r ec l a i m sf o r
type 2 diabetes than for type 1 di-
abetes if no claims for an oral antidi-
abetic drug.
1b.Patients withatleast two prescription
claims for antidiabetic drugs (either a
single agent or multiple agents) ﬁlled
in the baseline period were also in-
cluded in the study if they did not
meetcriterion1a,astepthatrepresents
the aforementioned modiﬁcation to
the base Healthcare Effectiveness Data
and Information Set criteria.
2. Atleast18yearsofageatstartofbaseline
period.
3. Continuous enrollment and pharmacy
beneﬁts throughout the 24-month
study period, except in the case of in-
patient death due to an acute cardio-
vascularcauseintheevaluationperiod.
Study variables
The dependent variable was a dichoto-
mous composite indicator for the occur-
rence of any of the following ACVEs
during the evaluation period: coronary
arterybypassgraft,revascularization,per-
cutaneous coronary intervention, acute
myocardial infarction (AMI), or incident
unstable angina (UA). Coronary artery
bypass graft, revascularization, and per-
cutaneous coronary intervention were
identiﬁed by the presence of at least one
inpatient or one outpatient claim with an
ICD-9-CM or Current Procedural Termi-
nology code for the speciﬁc procedure.
AMI and incident UA were identiﬁed
by the presence of at least one inpatient
claim with an ICD-9-CM diagnosis code
in any position for AMI (410.xx) or UA
(411.13), respectively; patients who had
anyinpatient oroutpatientnondiagnostic
claims with a diagnosis code for UA dur-
ing the baseline period were precluded
from being ﬂagged as having incident
UA during the evaluation period.
The primary independent variable
was a dichotomous indicator for the
occurrence of HEs during the evaluation
period, identiﬁed by the presence of at
least one outpatient claim with an ICD-9-
CM diagnosis code for hypoglycemia in
any position (251.03, 251.13, 251.23,
250.83)( 1 6 ) .
Although the service date of an out-
patient claim with a diagnosis of hypo-
glycemia will accurately represent the
time at which a patient sought medical
attention for hypoglycemic symptoms, it
is possible that the true onset of HEs may
have occurred days or weeks before the
patient was actually compelled to seek
care in response (17,18). Therefore, to al-
low for the possibility of such situations,
for the primary models a ﬂexible ap-
proach was adopted in which recorded
HEs were not strictly required to tempo-
rally precede recorded ACVEs; that is,
HEs were allowed to occur at any time
during the evaluation period, including
after ACVEs. This ﬂexible approach was
also subjected to sensitivity analyses as
described below.
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Johnston and AssociatesSeveral other important covariates
that might confound the relationship
between HEs and ACVEs were measured
during the baseline period: patient de-
mographics (age, sex, insurance plan
type, U.S. Census Bureau geographic re-
gion), baseline risk factors for coronary
artery disease as suggested by the Amer-
ican College of Cardiology and American
Heart Association (19) (hypercholesterol-
emia, hypertension, peripheral vascular
disease, chronic kidney disease), baseline
microvascular diabetes complications
(diabetic peripheral neuropathy, diabetic
retinopathy, leg and foot amputation),
indices of baseline health status and
healthcare resource use (Deyo–Charlson
comorbidity index [20], Agency for
Healthcare and Research Quality comor-
bidity index [21], count of medical en-
counters with a diagnosis of diabetes,
total baseline healthcare expenditures),
and baseline occurrence of ACVEs.
Other descriptive information col-
lected during the baseline period in-
cluded diabetes treatment regimens and
the use of cardiovascular medications
(antiplatelet agents, ACE inhibitors,
b-blockers, calcium channel blockers,
antihyperlipidemic drugs, other antihy-
pertensive agents, and anticoagulants).
Statistical analysis
Bivariate descriptive statistics were used to
testforstatisticallysigniﬁcantdifferencesin
all study variables between patients who
did and did not experience HEs during the
evaluationperiod.x
2testsforhomogeneity
wereusedtotestfordifferencesincategoric
variables; two-tailed Student t tests were
used to test for differences in continuous
variables. A P value of 0.05 was the maxi-
mum P value for which differences were
considered statistically signiﬁcant.
Multiple logistic regression was used
to examine the association between HEs
occurring during the evaluation period
and any ACVE occurring during the
evaluation period. Themodelswere ﬁtted
to the data using backward stepwise
selection applied to an a priori model
speciﬁcation that expressed the probabil-
ity of any ACVE as a function of the
dichotomous variable for HEs in the
evaluation period and covariates for pa-
tients’ baseline demographics, baseline
risk factors for coronary artery disease,
baseline microvascular diabetes compli-
cations, baseline indices of health status
and healthcare resource use, and baseline
occurrence of ACVEs. Variables were re-
tained in the models if they had a P value
Table 1—Characteristics and outcomes of patients with type 2 diabetes
Type 2 diabetic
patients with
coded HEs
Type 2 diabetic
patients without
coded HEs
N = 27,065 (3.1%) N = 833,780 (96.9%) P value
Age (years), mean (SD) 64.0 (13.2) 60.6 (13.0) ,0.001
Female (%) 47.7 48.7
Insurance plan type (%) ,0.001
Capitated payment
arrangements 18.2 16.4
Fee-for-service 80.7 82.2
Unknown 1.1 1.4
Geographic region (%) ,0.001
Northeast 7.5 8.8
North Central 37.2 32.8
South 35.6 41.8
West 19.4 16.2
Unknown 0.3 0.4
Risk factors for coronary artery
disease (%)
Hypercholesterolemia 1.8 2.1 ,0.001
Hypertension 28.1 23.0 ,0.001
Peripheral vascular disease 6.4 1.9 ,0.001
Chronic kidney disease 9.0 2.6 ,0.001
Diabetes complications (%)
Diabetic peripheral
neuropathy 9.8 2.7 ,0.001
Diabetic retinopathy 5.6 1.7 ,0.001
Leg and foot amputation 1.1 0.1 ,0.001
Medical encounters with
a diagnosis of diabetes,
mean (SD) 6.2 (8.3) 2.9 (3.7) ,0.001
Median 4 2
Deyo–Charlson comorbidity index,
mean (SD) 2.5 (2.0) 1.6 (1.4) ,0.001
Median 2 1
AHRQ comorbidity index,
mean (SD) 0.8 (1.3) 0.5 (0.9) ,0.001
Median 0 0
Cardiovascular medication (%)
Antiplatelet agents 17.1 9.3 ,0.001
ACE inhibitors 47.0 40.6 ,0.001
b-Blockers 43.4 32.5 ,0.001
Calcium channel blockers 29.1 23.3 ,0.001
Antihyperlipidemic drugs 69.3 64.2 ,0.001
Hypotensive agents 12.0 6.9 ,0.001
Anticoagulants 10.4 6.2 ,0.001
Total expenditures, mean (SD) $21,408 ($40,081) $11,660 ($24,048) ,0.001
Median $10,560 $5,919
Diabetes treatment allowing for
15-day gap (%)
Monotherapy with oral
antidiabetic agent 22.0 34.0
$2 oral antidiabetic agents 14.8 16.5
Oral antidiabetic agent(s) +
one insulin type 15.0 5.7
Oral antidiabetic agent(s) +
two or more insulin type(s) 5.7 1.6
One insulin type only 11.0 3.0
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Hypoglycemia and acute cardiovascular eventsthat was less than or equal to the maxi-
mum P value selection criterion of 0.01, a
conservative criterion chosen because
of the study’s very large sample size, re-
ported below. Model results are presented
as odds ratios with 95% CIs. All analyses
were conducted using SAS 9.1 and 9.2
(SAS Institute Inc., Cary, NC).
Sensitivity analysis
To test the sensitivity of study ﬁndings to
the more conservative approach that re-
quires an HE to occur before an ACVE
when establishing an association between
the two events, a secondary independent
variable was created. This secondary in-
dependent variable was a dichotomous
indicator for the occurrence of HEs in the
period from 1 to 365 days immediately
preceding the date of an ACVE; that is,
such HEs were required to be temporally
precedent to the ACVE.
The sensitivity analysis used a mod-
eling approach, speciﬁcation, and vari-
able selection criteria that were otherwise
identical to those used in the primary
models.
RESULTS—A total of 1,852,285 pa-
tients met the patient selection criteria
between 30 September 2006 and 30
September 2007. A total of 984,671
patients were excluded because they did
not have continuous enrollment and
pharmacy beneﬁts throughout the 24-
month study period; this is exclusive of
505 patients who experienced inpatient
death resulting from an acute cardiovas-
cular cause during the evaluation period.
These patients were exempted from the
continuous enrollment criteria. A further
6,769 patients were excluded because
they were less than 18 years of age. The
ﬁnal study cohort comprised 860,845
patients with type 2 diabetes.
Table 1 presents the demographic
and clinical characteristics of the study
sample. A total of 27,065 patients
(3.1%) experienced HEs in the evaluation
period. Patients with HEs in the evalua-
tion period were signiﬁcantly older than
patients without such HEs (average age of
64.0 years vs. 60.6 years; P , 0.001). Pa-
tients with HEs in the evaluation period
tended to be sicker than patients without
such HEs, as indicated by higher propor-
tions of patients having evidence of each
of the risk factors for coronary artery dis-
ease (P , 0.001), comorbid conditions
(P , 0.001), and higher mean baseline
total expenditures ($21,408 vs. $11,660;
P , 0.001).
Table 1 also presents rates of ACVEs
during the baseline and evaluation peri-
ods for the study sample. The rate of any
ACVEs was more than twice as high in
patientswithHEsintheevaluationperiod
compared with patients without such
HEs (5.3 vs. 2.2%; P , 0.001).
Table 2 presents the results of the lo-
gistic regression of the probability of any
ACVEs during the evaluation period, ﬁt-
ted on two different samples: 1) patients
ofallagesand2) patientsaged$65years.
Patients of all ages with HEs during the
evaluation period had 78.8% higher
regression-adjusted odds of experiencing
any ACVE during the evaluation period
than patients without such HEs. Patients
aged 65 years or older with HEs during
the evaluation period had 77.8% higher
regression-adjusted odds of experiencing
any ACVE during the evaluation period
than patients without such HEs.
The results for the sensitivity analysis
in which the HEs were required to be
temporally precedent to ACVEs indicate
thatpatientsofallageswithHEsthatwere
temporally precedent to ACVEs had
26.7% higher regression-adjusted odds
of experiencing any ACVE during the
evaluation period than patients without
such HEs (data not shown); patients aged
$65 years with temporally precedent HEs
had 21.4% higher regression-adjusted
odds of experiencing any ACVE during
theevaluationperiodthanpatientswithout
such HEs (data not shown).
CONCLUSIONS—Toourknowledge,
this is the ﬁrst retrospective observational
study to quantify the association between
HEsandACVEsinU.S.patientswithtype
2d i a b e t e s .
Ourstudyresultscontributeuniquely
to the body of recent ﬁndings related to
the complex relationship between hy-
poglycemia and adverse outcomes. The
ACCORD trial compared the effect of
intensive glycemic control (target A1C
,6.0%) with standard glycemic control
(target A1C 7.0–7.9%) on the risk of car-
diovascular events in patients with type 2
diabetes. Over a mean of 3.5 years of
follow-up, all-cause mortality was signif-
icantly greater in the intensive-therapy
groupthaninthestandard-therapygroup
(hazardratio1.22;95%CI1.01–1.46;P=
0.04), which led to an early discontinua-
tion of intensive therapy. Hypoglycemia
was found to be more common among
the patients in the intensive-therapy
Table 1—Continued
Type 2 diabetic
patients with
coded HEs
Type 2 diabetic
patients without
coded HEs
N = 27,065 (3.1%) N = 833,780 (96.9%) P value
$2 insulin types only 7.4 1.8
,45 days oral antidiabetic
agent(s) 4.1 6.1
No oral antidiabetic agent(s)
and no insulin use 20.1 31.2
ACVE evaluation period (%)
Coronary artery bypass graft 0.30 0.10 ,0.001
Revascularization 0.40 0.20 ,0.001
Percutaneous coronary
intervention 2.30 1.20 ,0.001
Incident UA 1.50 0.70 ,0.001
AMI 2.60 0.80 ,0.001
Any ACVE 5.30 2.20 ,0.001
Inpatient death related to ACVE 0.20 0.10 ,0.001
ACVE baseline period (%)
Coronary artery bypass graft 0.30 0.20 0.001
Revascularization 0.40 0.20 ,0.001
Percutaneous coronary
intervention 2.30 1.30 ,0.001
UA 1.80 0.90 ,0.001
AMI 1.70 0.80 ,0.001
Any ACVE 4.60 2.30 ,0.001
AHRQ, Agency for Healthcare Research and Quality.
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Johnston and Associatesgroup and was initially suggested as a po-
tential explanation for the excess mortal-
ity. Further analysis, however, suggested
that severe hypoglycemia did not explain
the excess mortality in the intensively
treated patients, but instead was associ-
ated with an increased risk of death
within each study arm (14). The VADT
examined the effects of intensive glucose
control on cardiovascular events in pa-
tients with long-standing type 2 diabetes.
VADT investigators found that intensive
glucose control did not lead to a signiﬁ-
canteffectontheratesofmajorcardiovas-
cular events, death, or microvascular
complications. However, a signiﬁcant in-
crease in the relative risk of sudden death
w a so b s e r v e di np a t i e n t sw i t hm o r et h a n
one episode of severe hypoglycemia (15).
The data source for this study could not
identifymortality with ahigh level ofsen-
sitivity and therefore focused on ICD-9-
CM–coded ACVEs.Despitethedifference
in outcomes between this and the afore-
mentioned studies, the ﬁndings of this
study add information that is suggestive
of an association between hypoglycemia
and cardiovascular morbidity. More
large-scale retrospective studies of real-
world data such as this one would be
useful to further explore the association
between hypoglycemia and cardiovascu-
lar and all-cause mortality.
These results neither suggest nor
address any role of glycemic control in
the relationship between hypoglycemic
episodes and the risk of ACVEs and thus
do not negate the importance of good
glycemic control. The evidence base
supporting a reduction in microvascular
complications with tight glycemiccontrol
in both type 1 and type 2 diabetes is
unequivocal. In fact, a joint statement by
the American Diabetes Association,
American College of Cardiology Founda-
tion, and American Heart Association
suggested no need for major changes in
glycemic control targets (15). Further-
more, a recent post hoc analysis of
ACCORD data examining the epidemio-
logic relationships between A1C and all-
cause mortality veriﬁed the expected
positive correlation between these factors;
the risk of death in intensively treated pa-
tients was explained by factors associated
with A1C persisting at .7% as opposed
to decreased A1C (22).
HEs were identiﬁed by the presence
of an outpatient medical claim with an
ICD-9-CM diagnosis code that is indica-
tive of hypoglycemia. Current ICD-9-CM
diagnosis coding for hypoglycemia lacks
speciﬁcity regarding clinical factors such
as plasma glucose levels and therefore
may reﬂect a wide continuum of severity.
The set of ICD-9-CM diagnosis codes was
chosen on the basis of their inclusion in
prior peer-reviewed publications in
which HEs had been identiﬁed within
administrative claims data (23,24). Find-
ings from these prior studies suggest that
because all HEs were identiﬁed through
ICD-9-CM diagnosis coding, these events
are likely to have been sufﬁciently severe
astorequireapatienttoseekmedicalcare
or to require intervention. Consequently,
there likely were many more episodes of
hypoglycemia, particularly those that are
mild in nature, that were not captured in
this study. A validation study of the ICD-
9-CM code set used in this analysis indi-
cates that these codes possessed relatively
high sensitivity for medically attended
HEs (16). Nevertheless, some coded in-
stancesofhypoglycemiawithinthisstudy
may be false positives, and the true sen-
sitivity of the codes could not be de-
termined in the validation study. The
potential impact of misclassiﬁcation de-
pends on the nature of the error and the
cardiovascular risk proﬁle and outcomes
of the misclassiﬁed subjects. If the false
negatives had an elevated risk and inci-
dence of ACVEs compared with true neg-
atives, misclassiﬁcation would have
resulted in a bias toward the null hypoth-
esis and would have weakened the asso-
ciation that we detected. In the opposite
case, misclassiﬁcation would suggest that
theriskisactuallyhighestinpatientswith
events that require a patient to seek med-
ical care or to require intervention. If false
positivesdidnothaveanelevatedriskand
incidence of ACVEs compared with true
negatives, then misclassiﬁcation would
again have resulted in a bias toward the
null hypothesis and would have weak-
ened the association that we detected. In
the opposite case, misclassiﬁcation would
have resulted in a bias toward rejecting the
null hypothesis and erroneously strength-
ened the association that we detected.
However,many ofthe false positives noted
in the validation study were those in-
dividuals who were coded with 250.83
and had a codiagnosis of secondary
diabeticglycogenosis,ulcersofthelower
extremity, cellulitis, diabetic lipidosis,
Oppenheim–Urbach syndrome, or oste-
omyelitis. Thus, the bias of such false
positives would be of concern if such in-
dividuals had an increased risk of ACVEs
beyondwhatwasadjustedforinthemul-
tivariate analyses.
The date of an outpatient diagnosis
for a medically attended HE may not be a
good approximation of the time at which
patients actually began experiencing such
Table 2—Results of multiple logistic regression of acute cardiovascular events as
a function of hypoglycemic events*
Independent variables
Patients of all ages† with
type 2 diabetes
Patients aged $65 years‡
with type 2 diabetes
Odds ratio 95% CI Odds ratio 95% CI
Coded HE in evaluation period 1.79 1.69–1.89 1.78 1.65–1.92
Age 65+ vs. 18–34 years 13.26 9.64–18.25 ——
Age 55–64 vs. 18–34 years 9.79 7.11–13.47 ——
Age 45–54 vs. 18–34 years 6.79 4.92–9.35 ——
Age 35–44 vs. 18–34 years 3.54 2.54–4.94 ——
Male vs. female 1.56 1.52–1.61 1.39 1.34–1.45
West vs. Northeast 0.82 0.77–0.88 0.86 0.79–0.93
Unknown vs. Northeast 0.97 0.73–1.29 0.80 0.42–1.50
South vs. Northeast 1.09 1.03–1.15 1.05 0.97–1.13
North Central vs. Northeast 1.19 1.13–1.26 1.16 1.08–1.24
Peripheral vascular disease 1.29 1.20–1.38 1.21 1.11–1.32
Chronic kidney disease 1.17 1.10–1.25 1.16 1.07–1.26
Diabetic peripheral neuropathy 1.10 1.03–1.18 ——
Diabetic retinopathy 1.33 1.23–1.44 1.24 1.11–1.38
Deyo–Charlson comorbidity index 1.05 1.04–1.06 1.05 1.04–1.07
Total baseline expenditures 1.76 1.70–1.83 1.56 1.48–1.64
Prior cardiovascular events 2.87 2.73–3.02 2.39 2.22–2.56
*Dependent variable = ACVEs in the evaluation period; models ﬁt using backward stepwise selection of
variables with P , 0.01. †Observations = 860,583; max-rescaled R
2 = 0.0651. ‡Observations = 316,695;
max-rescaled R
2 = 0.0322.
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Hypoglycemia and acute cardiovascular eventsevents (16–18). To address the unclear
nature of actual timing of the onset hypo-
glycemia, this study used two approaches,
one that did not require HEs to be tempo-
rally precedent to the ACVEs and one that
required the HEs to occur within 1 to 365
days before the ACVEs. Although explor-
atory analyses of the VADT trial data
found that severe hypoglycemia within
90 days was a strong predictor of cardio-
vascular mortality, retrospective epidemi-
ologic analysis of the ACCORDstudy data
found no temporal relationship between
hypoglycemia and death. Thus, our 365-
day timeframe for temporally precedent
HEs may be appropriate.
This study was subject to limitations.
The adjusted R
2 of the logistic regressions
was low; however, models in previous re-
search have demonstrated similar explan-
atory ability, highlighting the difﬁculty
of specifying a model that takes into
account a large proportion of the factors
that explain the variance in the occur-
rence of ACVEs (25). Because it is not fea-
sible to randomize diabetic patients to
hypoglycemia case and noncase groups,
this study used a retrospective observa-
tional study design. In the absence of ran-
domization, however, the possibility of
residual confounding may never be ruled
out. The association between HEs and
ACVEs may be partially driven by an in-
dependently higher baseline cardiovascu-
lar risk proﬁle, duration of disease, and
otherconfoundingfactorsthatarepresent
in patients who experience HEs. To ac-
count for such baseline differences and
identify the desired ceteris paribus asso-
ciation between HEs and ACVEs, we ad-
justedformultiplepotentialdemographic
and clinical confounders. In administra-
tive claims data, however, clinical infor-
mation is extracted from ICD-9-CM
diagnosis and various procedure coding
systems that are used by physicians to
support claims for reimbursement. Such
coding may result in misclassiﬁcation er-
ror if the codes are incorrectly recorded,
misused, or not recorded at all. A limita-
tion of this study that is shared by all ad-
ministrative claims-based retrospective
observational investigations is that the
true validity of the measured variables is
notknownwithcertainty.Thus,thestudy
results must be interpreted appropriately
as not representing proof of causal asso-
ciations.
This study’s real-world results com-
plement recent ﬁndings from more
restricted interventional or smaller obser-
vational settings and provide evidence
linking ICD-9-CM–coded outpatient
HEs to an increased risk of ACVEs in pa-
tientswithtype2diabetes.Thisistheﬁrst
large-scale retrospective observational
study addressing this association, so the
ﬁndings should be considered an initial
groundwork on which future research
and understanding can be built and im-
proved. Further studies of this relation-
ship are needed to inform clinicians on
t h ea m o u n to fc a r et h a ts h o u l db ea f -
forded to reducing the incidence of hypo-
glycemia in the treatment of patients with
type 2 diabetes.
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